Breaking News
Get 40% Off 0
🚨 Volatile Markets? Find Hidden Gems for Serious Outperformance
Find Stocks Now
Close

Jiangsu Recbio Technology Co Ltd (2179)

Create Alert
New!
Create Alert
Website
  • As an alert notification
  • To use this feature, make sure you are signed-in to your account
Mobile App
  • To use this feature, make sure you are signed-in to your account
  • Make sure you are signed-in with the same user profile

Condition

Frequency

Once
%

Frequency

Frequency

Delivery Method

Status

Add to/Remove from Watchlist Add to Watchlist
Add to Watchlist
Add Position

Position added successfully to:

Please name your holdings portfolio
 
9.24 +0.11    +1.20%
03:20:17 - Closed. Currency in HKD ( Disclaimer )
Type:  Equity
Market:  Hong Kong
ISIN:  CNE1000057K9 
  • Volume: 5,500
  • Bid/Ask: 0.00 / 0.00
  • Day's Range: 9.24 - 9.30
Jiangsu Recbio Technology 9.24 +0.11 +1.20%

Jiangsu Recbio Technology Co Ltd Company Profile

 
Get an in-depth profile of Jiangsu Recbio Technology Co Ltd, including a general overview of the company's business and key management, as well as employee data and location and contact information.
IndustryPharmaceuticals
SectorHealthcare
Employees

532

Equity Type

ORD

Jiangsu Recbio Technology Co., Ltd., a vaccine company, engages in the research, development, and commercialization of subunit vaccines in the People’s Republic of China. The company is developing vaccines for the treatment of cervical cancer, and anal and genital warts, including REC603, a recombinant human papillomavirus (HPV) 9-valent vaccine that is in phase III clinical trial; REC601 and REC602 recombinant HPV bivalent vaccines, which are in phase I clinical trials; REC604a, a recombinant HPV quadrivalent vaccine that is in pre-clinical stage; and REC604b, a recombinant HPV 9-valent vaccine that is in pre-clinical stage. It also develops ReCOV, a recombinant COVID-19 vaccine candidate that is in Phase II/III trial; R520A, a messenger ribonucleic acid COVID-19 vaccine candidate that is in pre-clinical stage; REC610, a recombinant shingles vaccine that is in Phase l clinical trial; REC607, a virus vectored adult tuberculosis vaccine that is in pre-clinical stage; REC606, a recombinant adult tuberculosis vaccine that is in pre-clinical stage; REC617, a recombinant influenza quadrivalent vaccine that is in pre-clinical stage; and REC605, a recombinant hand-foot-mouth disease quadrivalent vaccine that is in pre-clinical stage. Jiangsu Recbio Technology Co., Ltd. was founded in 2011 and is headquartered in Taizhou, the People’s Republic of China.

Contact Information

Address No. 888 Yaocheng Avenue Medical High-tech District
Taizhou,
China
Phone -
Fax -

Top Executives

Name Age Since Title
Yong Liu 49 2019 CEO, GM & Chairman of the Board
Feng Gao 61 2021 Independent Non-Executive Director
Ranting Qian 47 2021 Supervisor
Hongbin Zhou 50 2020 Non-Executive Director
Houwei Hu - 2023 Non-Executive Director
Weiwei Qiao 36 2021 Chairman of the Supervisory Board
Jiaxin Zhang - 2023 Non-Executive Director
Ming Fai Yuen 73 2021 Independent Non-Executive Director
Ping Liu 44 2022 Employee Representative Supervisor
Guodong Liang 71 2021 Independent Non-Executive Director
Feizhou Wang 56 2022 Supervisor
Lijun Xia 47 2021 Independent Non-Executive Director
Jianping Chen 46 2019 Vice GM & Executive Director
Kunxue Hong 59 2021 Chief Scientist & Non-Executive Director
Bu Li 47 2021 Vice GM & Executive Director
Qingqing Chen 41 2021 Vice GM, CFO, Secretary & Executive Director
Comment Guidelines

We encourage you to use comments to engage with other users, share your perspective and ask questions of authors and each other. However, in order to maintain the high level of discourse we’ve all come to value and expect, please keep the following criteria in mind:  

  •            Enrich the conversation, don’t trash it.

  •           Stay focused and on track. Only post material that’s relevant to the topic being discussed. 

  •           Be respectful. Even negative opinions can be framed positively and diplomatically. Avoid profanity, slander or personal attacks directed at an author or another user. Racism, sexism and other forms of discrimination will not be tolerated.

  • Use standard writing style. Include punctuation and upper and lower cases. Comments that are written in all caps and contain excessive use of symbols will be removed.
  • NOTE: Spam and/or promotional messages and comments containing links will be removed. Phone numbers, email addresses, links to personal or business websites, Skype/Telegram/WhatsApp etc. addresses (including links to groups) will also be removed; self-promotional material or business-related solicitations or PR (ie, contact me for signals/advice etc.), and/or any other comment that contains personal contact specifcs or advertising will be removed as well. In addition, any of the above-mentioned violations may result in suspension of your account.
  • Doxxing. We do not allow any sharing of private or personal contact or other information about any individual or organization. This will result in immediate suspension of the commentor and his or her account.
  • Don’t monopolize the conversation. We appreciate passion and conviction, but we also strongly believe in giving everyone a chance to air their point of view. Therefore, in addition to civil interaction, we expect commenters to offer their opinions succinctly and thoughtfully, but not so repeatedly that others are annoyed or offended. If we receive complaints about individuals who take over a thread or forum, we reserve the right to ban them from the site, without recourse.
  • Only English comments will be allowed.
  • Any comment you publish, together with your investing.com profile, will be public on investing.com and may be indexed and available through third party search engines, such as Google.

Perpetrators of spam or abuse will be deleted from the site and prohibited from future registration at Investing.com’s discretion.

2179 Comments

Write your thoughts about Jiangsu Recbio Technology Co Ltd
 
Are you sure you want to delete this chart?
 
Post
Post also to:
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Thanks for your comment. Please note that all comments are pending until approved by our moderators. It may therefore take some time before it appears on our website.
 
Are you sure you want to delete this chart?
 
Post
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Add Chart to Comment
Confirm Block

Are you sure you want to block %USER_NAME%?

By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.

%USER_NAME% was successfully added to your Block List

Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.

Report this comment

I feel that this comment is:

Comment flagged

Thank You!

Your report has been sent to our moderators for review
Continue with Google
or
Sign up with Email